U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07732218) titled 'Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial' on July 23.
Brief Summary: A single arm no randomized clinical trial evaluated the effectiveness and safety of once weekly semaglutide in adults with type 2 diabetes militus and obesity whose glycemic control remained inadequate despite standard therapy. participants received semaglutide for 16 weeks, beginning with 0.25mg weekly for 4 weeks followed by 0.5 mg weekly for 12 weeks. the primary outcome was the change in glycated hemoglobin, while secondary outcomes included changes in body weight, body mass index, blood glucose, bloo...